CN112813106A - Preparation method of zebra fish with LDLR gene deletion - Google Patents
Preparation method of zebra fish with LDLR gene deletion Download PDFInfo
- Publication number
- CN112813106A CN112813106A CN202110043825.1A CN202110043825A CN112813106A CN 112813106 A CN112813106 A CN 112813106A CN 202110043825 A CN202110043825 A CN 202110043825A CN 112813106 A CN112813106 A CN 112813106A
- Authority
- CN
- China
- Prior art keywords
- fish
- ldlr
- grna
- ldlr gene
- zebra fish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 24
- 101150013552 LDLR gene Proteins 0.000 title claims abstract description 22
- 238000012224 gene deletion Methods 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims description 11
- 238000000338 in vitro Methods 0.000 claims abstract description 25
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 24
- 241000251468 Actinopterygii Species 0.000 claims abstract description 16
- 108091033409 CRISPR Proteins 0.000 claims abstract description 14
- 230000035772 mutation Effects 0.000 claims abstract description 13
- 238000012216 screening Methods 0.000 claims abstract description 11
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 10
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 claims abstract description 7
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims abstract description 7
- 210000002257 embryonic structure Anatomy 0.000 claims abstract description 6
- 238000003209 gene knockout Methods 0.000 claims abstract description 5
- 238000009401 outcrossing Methods 0.000 claims abstract description 4
- 230000001568 sexual effect Effects 0.000 claims abstract description 4
- 208000005189 Embolism Diseases 0.000 claims abstract description 3
- 230000002792 vascular Effects 0.000 claims abstract description 3
- 238000013518 transcription Methods 0.000 claims description 21
- 230000035897 transcription Effects 0.000 claims description 21
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000000137 annealing Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 101150037123 APOE gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100027417 Cytochrome P450 1B1 Human genes 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000725164 Homo sapiens Cytochrome P450 1B1 Proteins 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 101710105047 Lipoprotein B Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010019644 Oligodendrocyte Transcription Factor 2 Proteins 0.000 description 1
- 102100026058 Oligodendrocyte transcription factor 2 Human genes 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention constructs LDLR gene deletion zebra fish by using CRISPR/Cas9 technology, and the specific steps comprise: 1) determining an LDLR target site according to the LDLR gene sequence; 2) preparing gRNA; 3) transcribing Cas9mR NA in vitro; 4) cas9mRNA and gRNA are mixed and injected into zebra fish embryos at the single cell stage; 5) f is to be0Feeding the embryo to sexual maturity; 6) outcrossing with wild adult fish, screening F0(ii) a 7) Selection of F producing efficient mutations0Selfing and screening F1(ii) a 8) From F1Selecting female fish and male fish with the same mutation from the generation mutants, and hybridizing to obtain F2Generation; 9) screening of L DLR Gene knockout homozygotesNamely the zebra fish with the LDLR gene deletion of stable inheritance. The LDLR gene deletion zebra fish constructed by the invention can be stably inherited and can be used for researching vascular embolism.
Description
Technical Field
The invention belongs to the field of molecular biology, and particularly relates to preparation of zebra fish with LDLR gene deletion.
Background
The death rate of cardiovascular diseases is very high, and the death rate of cardiovascular diseases becomes the first important cause of death of human diseases, wherein the most important pathological factor is atherosclerosis, which is promoted by multiple factors, generally, the atherosclerosis is infiltrated by immune cells on the inner wall of a large and medium arterial blood vessel, lipid substances such as cholesterol, lipoid and the like are adhered to the blood vessel wall, tissue hyperplasia such as lipid stripes, lipid nuclei, calcareous deposits, fibers and the like is generated, and finally hematoma rupture, massive hemorrhage, thrombus and the like are formed, so that a series of fat metabolism disorders, neurovascular dysfunction, lumen stenosis, artery elasticity reduction and the like are caused.
LDLR is one of low-density lipoprotein receptors and hepatocyte surface receptors, and binds Apoe to remove lipoprotein particles in blood, and also interacts with lipoprotein B on LDL particles to remove LDL from blood, which is very important for removing cholesterol and triglyceride-rich lipoprotein particles in blood.
The zebra fish is a third-large vertebrate model except rats and mice, is fertilized in vitro, developed in vitro, transparent in embryo, visible in development process and large in one-time egg laying quantity, and is a good animal model for researching cardiovascular diseases.
Disclosure of Invention
The invention aims to construct an LDLR gene deleted zebra fish by using a CRISPR/Cas9 system.
The preparation process of the invention is as follows:
the DNA sequence of the target site of the invention is as follows: 5'-GGTAGCTGGAAGTGTGATGG-3' are provided.
The invention provides a gene targeting kit, which comprises two Oligo sequences with the sequence of 5'-TAGGTAGCTGGAAGTGTGATGG-3', 5'-AAACCCATCACACTTCCAGCTA-3', and can be used for silencing LDLR gene expression.
The invention provides a gene knockout method, which comprises the following steps: the Oligo fragment is used for recognizing a target site of a target gene, binding with Cas9 and recognizing a PAM sequence at the target site, guiding nuclease to bind to the target site of the target gene, starting shearing to form a DSB gap, then connecting a cell with a repair mechanism through a non-homologous end to repair a double chain of the target gene, causing frameshift mutation, and finally knocking out the target gene.
Further, the target point is one or more than one.
Further, the invention provides a preparation method of the zebra fish with the LDLR gene deletion, which comprises the following steps:
1. determining an LDLR target site according to the LDLR gene sequence;
2. designing an Oligo sequence according to the LDLR target site;
3. constructing a gRNA in vitro transcription vector;
4, PCR to obtain a gRNA in vitro transcription template;
5. carrying out in-vitro transcription on the template obtained in the step 4 to obtain gRNA;
6. preparing an in vitro transcription template of Cas9 mRNA;
7. transcribing Cas9mRNA in vitro;
8. adding a polyA sequence, and recovering Cas9 mRNA;
9. cas9mRNA and gRNA are mixed and injected into zebra fish embryos at the single cell stage;
10. f is to be0Feeding the embryo to sexual maturity;
11. outcrossing with wild adult fish, screening F0;
12. Selection of F producing efficient mutations0Selfing and screening F1;
13. Selecting female fish and male fish with the same mutation from the F1 generation mutants, and hybridizing to obtain F2 generation;
14. screening LDLR gene knockout homozygote to obtain the stably inherited LDLR gene deletion zebra fish.
The invention has the advantages that:
the zebra fish with the LDLR gene deletion constructed by the invention is the first case at home and abroad.
The LDLR gene deletion zebra fish constructed by the invention can be stably inherited and can be used for researching vascular embolism.
Drawings
FIG. 1: electrophoretic picture of clone framework pT7-gRNA-Bbs I
FIG. 2: PCR identification of bacterial liquid
FIG. 3: gRNA in vitro transcription template
FIG. 4: in vitro transcription of Cas9mRNA
FIG. 5: PCR and enzyme digestion identification mutant
FIG. 6: comparing CYP1B1 gene-deleted zebra fish with wild type sequence
Detailed Description
The present invention is further illustrated in detail by the following examples, which are provided only for illustrating the present invention and are not intended to limit the scope of the present invention.
Example 1: preparation of animal models of the invention
1. Laboratory animal
Wild type zebra fish (strain TU) were bred according to a standardized protocol with water temperature of 28.5 ℃ and light/dark cycle of 14h/10h, adult zebra fish were spawned and embryo collected and bred in E3 hatching fluid, and embryo and larval stages of development were expressed in hours of fertilization (hpf) or days of fertilization (dpf).
CRISPR/Cas9 Gene knockout target site design
Inquiring a zebra fish LDLR gene sequence on NCBI, designing an LDLR target site on http:// zifit.partners.org/ZiFiT/CSquarere 9 nucleic.aspx according to a CRISPR/Cas9 knockout principle, wherein the target site comprises 20 bases, and the selection standard of the target site is as follows: 5 '-GG- (N) 18-NGG-3'; wherein the 5 'GG dinucleotide is part of the T7 promoter, and the 3' end of the target site is NGG.
3. Construction of gRNA in vitro transcription vector
3.1 the gRNA cloning backbone pT7-gRNA-Bbs I was obtained by digesting pT7-gRNA with Bbs I and recovering the gel (see FIG. 1), the digestion system is shown in the following Table 1:
table 1 enzyme system:
3.2 ordering two oligos according to target site, oligo1 sequence 5'-TAGGTAGCTGGAAGTGTGATGG-3', oligo2 sequence 5'-AAACCCATCACACTTCCAGCTA-3';
3.3 using ddH2O respectively dissolving the oligos into 10 mu M solution, and annealing to obtain small sticky end fragments, wherein the annealing procedure is shown in Table 2;
TABLE 2 annealing procedure
3.4 the annealed fragment is connected with the recovered gRNA cloning skeleton pT7-gRNA-Bbs I, transformed, picked and cloned, the RV-M and Oligo2 are used as primers to carry out the PCR identification of bacterial liquid (annealing at 58 ℃, extending for 30sec, 30 cycles), the target band is about 130bp (shown in figure 2), the positive clone is picked and sent to sequencing, and clone glycerol with correct sequence is selected for preserving bacteria, improving grains, and RV-M sequence: 5'-AGCGGATAACAATTTCACACAGGA-3', see Table 3 for the linkage system;
TABLE 3 connection System
4. Preparation of gRNA
4.1 using T7-cr fwd and tracr rev primer pair, using constructed gRNA in vitro transcription vector as template, obtaining gRNA in vitro transcription template (annealing at 58 ℃, extending for 30sec, 40cycle, 40 mul system) by using high fidelity enzyme PCR, taking 1 mul PCR product for electrophoresis, directly recovering PCR product after confirming single band (125bp) (see figure 3), for subsequent experiment, T7-cr fwd sequence: 5'-GAAATTAATACGACTCACTATA-3', tracr rev sequence: 5'-AAAAAAAGCACCGACTCGGTGCCAC-3', respectively;
4.2 in vitro transcription of gRNAs
The gRNA in vitro transcription system is shown in Table 4;
TABLE 4 in vitro transcription of mRNA reaction System
4.3 recovery of gRNA
4.3.1 RNase-free water was used to dilute the gRNA transcript to 300. mu.l, 330. mu.l of absolute ethanol was added;
4.3.2 adding the solution into a recovery column, centrifuging for 15s at 10000 g/min;
4.3.3 adding 700 mul of miRNA Wash Solution I, and centrifuging for 5-10 s;
4.3.4 adding 500 μ l of Wash Solution II, centrifuging for 5-10s, and repeating once;
4.3.5 discarding the liquid in the collecting pipe, centrifuging for 1min, and removing the residual liquid;
4.3.6 adding a proper amount of RNase-free water preheated at 95 ℃, centrifuging at the maximum rotating speed for 20-30s, and collecting a gRNA solution;
5. preparation of Cas9mRNA
5.1 preparation of in vitro transcription template for Cas9 mRNA: the pSP6-2sNLS-spCas9 vector (37 ℃, 4h or more) was linearized by Xba I single digestion; taking a small amount of electrophoresis to confirm that linearization is complete, and directly recovering a linearization product;
5.2 in vitro transcription of Cas9mRNA, the mRNA in vitro transcription system is shown in Table 5;
TABLE 5 Cas9mRNA in vitro transcription System
5.3 addition of polyA sequence, mRNA recovered (FIG. 4) can be used for microinjection;
TABLE 6 mRNA plus polyA reaction System
6. Preparation F0Zebra fish substitute
6.1 mixing Cas9mRNA and gRNA, injecting into a zebra fish embryo of a single cell, and simultaneously taking the same batch of uninjected embryos as a control, wherein Cas9mRNA 300-500pg and gRNA 25-200 pg;
6.2 taking the embryo with normal phenotype after 2-4dpf injection, extracting genome DNA, and detecting the mutation efficiency of the target site by PCR and T7E1 enzyme digestion (figure 5);
6.3 recovering the uncut band, TA cloning and sequencing, and detecting the mutation type;
6.4 selection of F for injection in the same batch with higher mutation efficiency and higher survival rate0Feeding the embryo to sexual maturity;
6.5 carrying out outcrossing with wild adult fish, mixing 3-5F 1 embryos with 1dpf into a group to extract genome DNA;
6.6 detecting the mutation condition of the target site by PCR and enzyme digestion;
6.7 recovering the band which is not cut, TA clone sequencing and determining the mutation type;
6.8 selection of F producing potent mutations0Mating fish and breeding in large quantities F1。
7. Screening for F carrying the mutation at the target site1Adult fish
7.1 mixing F1Raising to be large enough until tail fins are suitable to be cut;
7.2F1cutting tail fin and extracting gene group of adult fish, carrying out gene detection one by PCR and enzyme digestion, and screening out F1Heterozygote;
7.3 recovering the band which is not cut open and TA clone, sequencing and determining the mutation type;
8. selecting female fish and male fish with the same mutation from the F1 generation mutation body weight, hybridizing to obtain F2 generation, culturing at 28.5 ℃, taking partial embryos at 4dpf, independently extracting genome DNA of each embryo, and taking primer pairs with the following primer sequences:
9. the efficiency of identifying homozygous mutations by PCR banding analysis was further identified by sequencing (figure 5).
Claims (2)
- The preparation method of the zebra fish with the LDLR gene deletion is characterized by comprising the following steps:1) determining an LDLR target site according to the LDLR gene sequence;2) designing an Oligo sequence according to the LDLR target site;3) constructing a gRNA in vitro transcription vector;4) PCR is carried out to obtain a gRNA in vitro transcription template;5) carrying out in-vitro transcription on the template obtained in the step 4 to obtain gRNA;6) preparing an in vitro transcription template of Cas9 mRNA;7) in vitro transcription of Cas9mRNA;8) Adding a polyA sequence, and recovering Cas9 mRNA;9) cas9mRNA and gRNA are mixed and injected into zebra fish embryos at the single cell stage;10) f is to be0Feeding the embryo to sexual maturity;11) outcrossing with wild adult fish, screening F0;12) Selection of F producing efficient mutations0Selfing and screening F1;13) From F1Selecting female fish and male fish with the same mutation from the generation mutants, and hybridizing to obtain F2Generation;14) screening LDLR gene knockout homozygote to obtain the stably inherited LDLR gene deletion zebra fish.
- 2. The use of the LDLR gene deleted zebrafish of claim 1, wherein the LDLR gene deleted zebrafish is used for the study of vascular embolism.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110043825.1A CN112813106A (en) | 2021-01-13 | 2021-01-13 | Preparation method of zebra fish with LDLR gene deletion |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110043825.1A CN112813106A (en) | 2021-01-13 | 2021-01-13 | Preparation method of zebra fish with LDLR gene deletion |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112813106A true CN112813106A (en) | 2021-05-18 |
Family
ID=75869249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110043825.1A Withdrawn CN112813106A (en) | 2021-01-13 | 2021-01-13 | Preparation method of zebra fish with LDLR gene deletion |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112813106A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105647969A (en) * | 2016-02-16 | 2016-06-08 | 湖南师范大学 | Method for breeding stat1a (signal transducer and activator of transcription 1) gene-deleted zebra fish through gene knockout |
US20190037817A1 (en) * | 2016-02-01 | 2019-02-07 | Hebei Invivo Biotech Inc | Ldl receptor gene knockout, genetically-engineered hamster |
-
2021
- 2021-01-13 CN CN202110043825.1A patent/CN112813106A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190037817A1 (en) * | 2016-02-01 | 2019-02-07 | Hebei Invivo Biotech Inc | Ldl receptor gene knockout, genetically-engineered hamster |
CN105647969A (en) * | 2016-02-16 | 2016-06-08 | 湖南师范大学 | Method for breeding stat1a (signal transducer and activator of transcription 1) gene-deleted zebra fish through gene knockout |
Non-Patent Citations (2)
Title |
---|
LIU C 等: "Modeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafish", 《J LIPID RES》 * |
无: "Accession. XM_005163870.4,PREDICTED: Danio rerio low density lipoprotein receptor a (ldlra), transcript variant X1, mRNA", 《GENBANK》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107475300B (en) | Construction method and application of Ifit3-eKO1 gene knockout mouse animal model | |
CN106047930B (en) | Preparation method of Flox rat with conditional knockout of PS1 gene | |
CN106318934B (en) | Gene complete sequence of carrot β (1,2) xylose transferase and plasmid construction of CRISPR/CAS9 for transfecting dicotyledonous plants | |
AU2017101108A4 (en) | Construction method of animal model of mucopolysaccharidosis type II and use thereof | |
EP3381278B1 (en) | Method for preparing a canine model of atherosclerosis | |
CN106244557A (en) | Rite-directed mutagenesis ApoE gene and the method for LDLR gene | |
CN110684777B (en) | Application of isolated nucleotide sequence in construction of zebra fish with reduced intramuscular stings | |
CN113736787A (en) | gRNA of targeted mouse Atp7b gene and method for constructing Wilson disease mouse model | |
CN110643636A (en) | Megalobrama amblycephala MSTNa & b gene knockout method and application | |
CN105274141A (en) | Transgenic vector for target mutation of primordial germ cells, method for preparing transgenic vector and application thereof | |
CN108866102B (en) | Construction method of Adgrv1 gene Y6236fsX1 mutant animal model | |
CN112410341B (en) | Mouse model construction method capable of inducing specific elimination of neutrophils | |
CN110066805A (en) | The method of gene knockout breeding adgrf3b Gene Deletion zebra fish | |
CN106282230A (en) | The method of rite-directed mutagenesis LDLR gene | |
CN108018315A (en) | A kind of application of separated gene order in the blue or green Medaka albefaction strain of Japan is prepared | |
CN108251456B (en) | Preparation method of atherosclerosis mouse model with NOD genetic background | |
CN113249409A (en) | BMI1 gene-deleted zebra fish | |
CN112695034A (en) | Preparation method of zebra fish with ApoE gene deletion | |
CN112680479A (en) | Preparation method of zebra fish with CYP1B1 gene deletion | |
CN112813106A (en) | Preparation method of zebra fish with LDLR gene deletion | |
CN106244556A (en) | The method of rite-directed mutagenesis ApoE gene | |
CN113558011A (en) | Method for establishing sjogren syndrome animal model based on gamma-secretase activated protein gene | |
CN111972355A (en) | Mouse model of GSDIa type glycogen storage disease and construction method thereof | |
CN113215199A (en) | Klotho+/-Gene deletion zebra fish | |
CN110331172B (en) | Method for constructing whitened hamster model based on CRISPR-Cas9 system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210518 |
|
WW01 | Invention patent application withdrawn after publication |